Mobidiag, Molecular In Vitro Solutions for Syndromic Diagnostics
Established in 2000, Mobidiag develops innovative solutions to advance the diagnosis of infectious diseases and serves the European clinical diagnostics market since 2008. Mobidiag addresses both high to medium volume screening with the Amplidiag® Easy platform, bringing the Amplidiag® IVD PCR kits further by automating the workflow, and the upcoming Novodiag® platform (CE-IVD mark pending) showcased at the ECCMID 2017 and associated panels for a fully automated solution and suitable for smaller volumes and labs.
Now available! Amplidiag®, a family of multiplex diagnostic tests and platform for high-volume screening:
Amplidiag® H. pylori+ClariR
Amplidiag® Stool Parasites
Amplidiag® C. difficile+027
Amplidiag® Bacterial GE
All are compatible with Amplidiag® Easy, automated solution for extraction from primary tubes to PCR plate set-up.
Discover how Mobidiag can support you with rapid and reliable pathogen detection solutions with its upcoming Novodiag®, a turnkey solution for rapid and sensitive on-demand testing. Meet us at booth #100 at ECCMID 2017 (Vienna, Austria)!
Tags: Carbapenemase Resistant Enterobacteriaceae (CRE), Clostridium difficile, Vancomycin Resistant Enterococcus, Helicobacter pylori, Gastroenteritis
Date Published: April 14, 2017
Source article link: Mobidiag Oy (HQ) » company contact details
FDA Clears Identification of Mycobacteria, Nocardia and Moulds on VITEK® MS
FDA Clearance for ARIES C. difficile Assay Detecting both Toxin A and B
COPAN Diagnostics Inc. Showcasing PhenoMATRIX™ Smart Algorithms at AACC in San Diego
Disks for Simple, Efficient Confirmation of CPE and OXA-48
FDA Clearance for Solana® C. difficile Molecular Assay